[Fulminant hepatitis during the therapy for tuberculous meningitis].
Garavelli
P L
PL
Divisione di Malattie Infettive e Medicina Tropicale, Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, Alessandria.
D000328:Adult; D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006501:Hepatic Encephalopathy / Q000139:chemically induced*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects*; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D014390:Tuberculosis, Meningeal / Q000150:complications* / Q000188:drug therapy
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
Epatite fulminante in corso di terapia per meningite tubercolare.